Covered recipient · General Payments record
ALAN PARSA
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$157,283.75
188 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,369.75 | 27 |
| Compensation for serving as faculty or as a speaker for a medical education program | $24,225.00 | 9 |
| Travel and Lodging | $17,905.24 | 44 |
| Food and Beverage | $15,455.76 | 104 |
| Honoraria | $8,203.00 | 3 |
| Consulting Fee | $7,125.00 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Corcept Therapeutics | $74,691.96 | 55 |
| Novo Nordisk Inc | $27,619.95 | 41 |
| Abbott Laboratories | $18,973.48 | 24 |
| Dexcom, Inc. | $16,863.26 | 9 |
| Eli Lilly and Company | $11,987.03 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $5,493.43 | 15 |
| Lilly USA, LLC | $1,108.16 | 6 |
| Insulet Corporation | $183.83 | 12 |
| Neurocrine BioSciences, Inc. | $159.99 | 1 |
| Amgen Inc. | $70.42 | 3 |
| Bayer Healthcare Pharmaceuticals Inc. | $52.81 | 2 |
| Xeris Pharmaceuticals, Inc. | $49.37 | 2 |
| ABBVIE INC. | $30.06 | 1 |
Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ALAN PARSA
NPI 1215268362 · CMS profile ID 9273
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
HONOLULU, HI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215268362?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ALAN PARSA, NPI 1215268362, CMS profile ID 9273. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215268362?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ALAN PARSA, NPI 1215268362, CMS profile ID 9273. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215268362?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ALAN PARSA, NPI 1215268362, CMS profile ID 9273, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1215268362?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
188 matching records · $157,283.75 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 188.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $24.73 | 09/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186485781 | CMS |
| Insulet Corporation | $25.11 | 09/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207155687 | CMS |
| Corcept Therapeutics | $382.62 | 09/02/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143929 | CMS |
| Corcept Therapeutics | $21.08 | 09/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144075 | CMS |
| Novo Nordisk Inc | $1,162.50 | 08/29/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188384897 | CMS |
| Novo Nordisk Inc | $20.75 | 08/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189070070 | CMS |
| Novo Nordisk Inc | $1.56 | 08/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189078451 | CMS |
| Corcept Therapeutics | $630.00 | 08/27/2025 | Honoraria | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143915 | CMS |
| Novo Nordisk Inc | $27.41 | 08/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188360444 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $89.87 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223048474 | CMS |
| Novo Nordisk Inc | $25.73 | 08/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188852425 | CMS |
| Novo Nordisk Inc | $1.90 | 08/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189079080 | CMS |
| Corcept Therapeutics | $28.58 | 08/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144029 | CMS |
| Novo Nordisk Inc | $7.52 | 08/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188436664 | CMS |
| Abbott Laboratories | $129.57 | 08/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240963699 | CMS |
| Novo Nordisk Inc | $88.05 | 08/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189052638 | CMS |
| Corcept Therapeutics | $631.23 | 07/30/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144041 | CMS |
| Insulet Corporation | $19.33 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207152355 | CMS |
| Abbott Laboratories | $95.71 | 07/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240959428 | CMS |
| Novo Nordisk Inc | $3,022.50 | 07/24/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188249271 | CMS |
| Novo Nordisk Inc | $121.85 | 07/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188429472 | CMS |
| Abbott Laboratories | $1,425.00 | 07/21/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240585833 | CMS |
| Abbott Laboratories | $1,425.00 | 07/21/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240585836 | CMS |
| Insulet Corporation | $26.90 | 07/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207101207 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.11 | 07/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223048472 | CMS |
| Insulet Corporation | $11.37 | 07/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207100371 | CMS |
| Abbott Laboratories | $1,425.00 | 07/15/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240585824 | CMS |
| Abbott Laboratories | $1,425.00 | 07/15/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240585828 | CMS |
| Abbott Laboratories | $1,425.00 | 07/14/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240585816 | CMS |
| Abbott Laboratories | $1,900.00 | 07/14/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240585819 | CMS |
| Novo Nordisk Inc | $30.26 | 07/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188771603 | CMS |
| Abbott Laboratories | $17.84 | 06/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240949498 | CMS |
| Insulet Corporation | $8.66 | 06/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207148927 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32.15 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223048468 | CMS |
| Corcept Therapeutics | $2,800.00 | 06/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143845 | CMS |
| Corcept Therapeutics | $3,400.00 | 06/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143847 | CMS |
| Corcept Therapeutics | $4,900.00 | 06/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143849 | CMS |
| Corcept Therapeutics | $3,400.00 | 06/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143851 | CMS |
| Corcept Therapeutics | $4,900.00 | 06/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143853 | CMS |
| Corcept Therapeutics | $4,900.00 | 06/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143855 | CMS |
| Corcept Therapeutics | $125.17 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144033 | CMS |
| Corcept Therapeutics | $12.51 | 06/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144037 | CMS |
| Corcept Therapeutics | $14.72 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144043 | CMS |
| Corcept Therapeutics | $1,061.75 | 06/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143877 | CMS |
| Corcept Therapeutics | $2,518.86 | 06/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214143879 | CMS |
| Corcept Therapeutics | $135.00 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144035 | CMS |
| Corcept Therapeutics | $15.40 | 06/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144039 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.47 | 06/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223048470 | CMS |
| Dexcom, Inc. | $2,850.00 | 06/05/2025 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250466692 | CMS |
| Corcept Therapeutics | $63.95 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214144003 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,036,292.60 | 25 |
| PY2024 | Recipient | $93,997.00 | 4 |
| PY2024 | Principal investigator | $1,319,373.09 | 19 |
| PY2023 | Recipient | $1,333.38 | 3 |
| PY2023 | Principal investigator | $713,335.51 | 20 |
| PY2022 | Recipient | $446.00 | 1 |
| PY2022 | Principal investigator | $184,025.00 | 7 |
| PY2021 | Recipient | $86,960.15 | 2 |
| PY2021 | Principal investigator | $210,656.15 | 13 |
| PY2019 | Recipient | $2,957.53 | 2 |
| PY2019 | Principal investigator | $59,001.95 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
25 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity PACIFIC DIABETES & ENDOCRINE CENTER | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202532767 |
| Principal investigator 1 | ABBVIE INC. | $26,584.20 | 12/05/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202529302 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,600.00 | 11/25/2025 | Non-covered Recipient Entity Pacific Diabetes And Endocrine Center | BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. | No dispute reported | 06/30/2026 | 1225419843 |
| Principal investigator 1 | ABBVIE INC. | $23,367.15 | 11/05/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202521535 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,164.50 | 11/01/2025 | Non-covered Recipient Entity Pacific Diabetes And Endocrine Center | BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. | No dispute reported | 06/30/2026 | 1225419735 |
| Principal investigator 1 | ABBVIE INC. | $17,050.50 | 10/09/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202514237 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,368.00 | 09/19/2025 | Non-covered Recipient Entity Pacific Diabetes And Endocrine Center | BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. | No dispute reported | 06/30/2026 | 1225419819 |
| Principal investigator 1 | ABBVIE INC. | $19,522.35 | 09/04/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202508722 |
| Principal investigator 1 | ABBVIE INC. | $13,258.35 | 08/06/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202502638 |
| Principal investigator 1 | ABBVIE INC. | $7,079.40 | 07/02/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202495327 |
| Principal investigator 1 | Eli Lilly and Company | $237,227.66 | 06/09/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE RETATRUTIDE TREATMENT IN THE MAINTENANCE OF WEIGHT REDUCTION IN INDIVIDUALS WITH OBESITY | No dispute reported | 06/30/2026 | 1187888306 |
| Principal investigator 1 | Eli Lilly and Company | $1.65 | 06/09/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187889906 |
| Principal investigator 1 | ABBVIE INC. | $7,882.65 | 06/03/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202488871 |
| Principal investigator 1 | ABBVIE INC. | $11,126.70 | 05/07/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483971 |
| Principal investigator 1 | ABBVIE INC. | $3,030.75 | 04/03/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CTR | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202468996 |
| Principal investigator 1 | Eli Lilly and Company | $92,547.00 | 01/21/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187887744 |
| Principal investigator 1 | Eli Lilly and Company | $694.13 | 01/19/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187887748 |
| Principal investigator 1 | Eli Lilly and Company | $589.44 | 01/17/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187889352 |
| Principal investigator 1 | Eli Lilly and Company | $4,971.12 | 01/09/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187889350 |
| Principal investigator 1 | Eli Lilly and Company | $8,535.40 | 01/09/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | No dispute reported | 06/30/2026 | 1187889740 |
| Principal investigator 1 | Eli Lilly and Company | $148,591.00 | 01/07/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) | No dispute reported | 06/30/2026 | 1187887746 |
| Principal investigator 1 | Eli Lilly and Company | $264,209.00 | 01/07/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187889348 |
| Principal investigator 1 | Eli Lilly and Company | $91,673.00 | 01/07/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187889738 |
| Principal investigator 1 | Eli Lilly and Company | $41,928.00 | 01/07/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187889904 |
| Principal investigator 1 | Eli Lilly and Company | $1,770.65 | 01/06/2025 | Non-covered Recipient Entity PACIFIC DIABETES AND ENDOCRINE CENTER | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | No dispute reported | 06/30/2026 | 1187887484 |